Retatrutide: A Triple-Agonist Peptide on the Research Frontier

Retatrutide is the newest compound in the incretin research class and, at present, the most pharmacologically complex. Where Semaglutide activates one incretin receptor (GLP-1) and Tirzepatide activates two (GIP and GLP-1), Retatrutide activates three: GIP, GLP-1, and the glucagon receptor. That third receptor introduces mechanistic territory the earlier compounds do not cover — and clinical research published since 2023 has produced weight-reduction outcomes larger than any prior GLP-1-class compound.

Retatrutide is investigational. It has not received regulatory approval from any agency as of 2026 and is being developed by Eli Lilly through ongoing clinical trial programs. This article addresses Retatrutide as a research compound, covering its chemistry and triple-agonist mechanism, the clinical research that has positioned it as the most-watched compound in the category, and how it compares mechanistically to Tirzepatide and Semaglutide.

What Is Retatrutide?

Retatrutide is a synthetic peptide designed to activate three distinct G-protein-coupled receptors: the GIP receptor, the GLP-1 receptor, and the glucagon receptor. The compound was originally designated LY3437943 during preclinical development and was first published by Coskun and colleagues at Eli Lilly in 2022 [Ref. 1]. Like Tirzepatide, Retatrutide carries a fatty acid modification that binds reversibly to serum albumin, extending the half-life to approximately six days and supporting once-weekly dosing in clinical trials.

The compound’s structure represents a deliberate engineering challenge: producing a single peptide that engages three different receptors with balanced activity is significantly harder than designing a single-receptor or dual-receptor agonist. The receptor balance in Retatrutide is weighted toward GIP and glucagon activity, with somewhat lower relative GLP-1 potency than seen in single- or dual-agonist compounds — a deliberate design choice intended to amplify the metabolic and thermogenic contributions of the GIP and glucagon receptors.

Retatrutide remains in clinical trial development and has not received regulatory approval. Research-grade Retatrutide sold to qualified laboratories is for in vitro and animal research use only. There is no approved pharmaceutical version of Retatrutide currently on the market.

Mechanism of Action

Retatrutide’s triple-agonist mechanism extends the pharmacological territory established by GLP-1 mono-agonists and GIP/GLP-1 dual agonists. The first two receptor pathways — GLP-1 and GIP — produce the same effects discussed in the Tirzepatide research deep dive: glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, central satiety signaling, and the GIP-mediated effects on adipose tissue and bone metabolism.

The glucagon receptor pathway adds several mechanistic threads that distinguish Retatrutide from both Tirzepatide and Semaglutide.

Thermogenesis and energy expenditure. Glucagon receptor activation increases resting energy expenditure through effects on hepatic metabolism, brown adipose tissue activity, and substrate utilization. This thermogenic contribution is hypothesized to explain part of why Retatrutide has produced larger weight-reduction outcomes than dual or single agonists in early trials.

Hepatic lipid mobilization. Glucagon receptors are densely expressed in the liver, where activation promotes lipolysis, beta-oxidation, and reduced hepatic lipid accumulation. This makes Retatrutide of particular interest in research on metabolic dysfunction-associated steatotic liver disease (MASLD).

Glycemic complexity. Glucagon receptor activation tends to raise blood glucose, which is the opposite of the GLP-1 receptor effect. The balanced design of Retatrutide is intended to use GLP-1-mediated glucose-lowering to offset glucagon-mediated glucose-raising, producing net glycemic improvement while gaining the metabolic benefits of glucagon receptor activation [Ref. 5].

Synergistic appetite suppression. Combined activation of GLP-1, GIP, and glucagon receptors appears to produce appetite reduction beyond what any single or dual receptor activation produces alone, contributing to the compound’s weight-loss profile.

The mechanistic rationale for triple agonism — combining incretin and counter-regulatory hormone receptor activation in a single molecule — represents a notable departure from earlier compounds in the class and remains an active area of pharmacological research [Ref. 6].

Research Applications

Retatrutide’s research base is recent but expanding rapidly. The compound’s phase 2 program produced results in obesity, type 2 diabetes, and metabolic liver disease that established its position as the leading next-generation GLP-1-class compound.

Obesity research

The headline result for Retatrutide came from a phase 2 obesity trial published by Jastreboff and colleagues in the New England Journal of Medicine in 2023. At the highest dose tested (12 mg weekly), the trial reported approximately 24% mean body weight reduction at 48 weeks — the largest effect documented in any published GLP-1-class trial to date [Ref. 2]. The result substantially exceeded the approximately 20% observed with Tirzepatide in SURMOUNT-1 and the approximately 15% observed with Semaglutide in STEP 1.

Type 2 diabetes research

A separate phase 2 trial published by Rosenstock and colleagues in The Lancet in 2023 examined Retatrutide in subjects with type 2 diabetes [Ref. 3]. The compound produced substantial HbA1c reductions across the dose range tested, with body weight reductions tracking similarly to the obesity trial population.

Steatotic liver disease research

Retatrutide’s glucagon receptor activation makes it of particular interest for metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD). A 2024 phase 2 trial by Sanyal and colleagues reported reductions in liver fat content alongside weight and metabolic improvements [Ref. 4]. This research direction has no direct parallel in Semaglutide or Tirzepatide work, since neither of those compounds engages the glucagon receptor.

Emerging applications

Retatrutide’s phase 3 program is examining the compound in obesity (TRIUMPH series), type 2 diabetes, and obstructive sleep apnea. Additional research is exploring cardiovascular outcomes, kidney outcomes, and longer-term effects on body composition.

Across all research domains, research-grade Retatrutide is for laboratory research only. The compound has not been approved by any regulatory agency, and clinical trial participation through approved channels remains the only context for human use.

Dosing & Reconstitution for Research

Researchers working with lyophilized Retatrutide reconstitute the compound with bacteriostatic water before use. As with other fatty-acid-modified peptides in this class, Retatrutide’s molecular weight is high — approximately 4731 g/mol — meaning molar concentrations are relatively low for a given mass.

A 10 mg vial reconstituted with 2 mL of bacteriostatic water yields 5 mg/mL or approximately 1057 nmol/mL. A 5 mg vial in 2 mL yields 2.5 mg/mL or approximately 528 nmol/mL. As with other peptides in the GLP-1 research class, researchers should calculate concentrations in molar units when designing comparative protocols, since equivalent mass concentrations represent different molar quantities across compounds with different molecular weights.

Reconstitution technique follows the standard approach: inject bacteriostatic water down the inner wall of the vial rather than directly onto the lyophilized powder, then swirl gently until dissolved. Direct injection onto powder can cause foaming and may complicate concentration measurement.

Researchers can verify their concentration math against our peptide reconstitution calculator, which handles the conversion between mass and molar units automatically.

This article does not provide dosing guidance for any therapeutic indication. Retatrutide is investigational, and any human exposure should occur exclusively through approved clinical trials under medical supervision.

Storage & Handling

Lyophilized Retatrutide is stable at room temperature during shipping but should be moved to long-term storage at -20°C (-4°F), protected from light, on receipt. Under proper lyophilized conditions, the compound remains stable for 24 months or longer.

Once reconstituted, Retatrutide should be stored at 2–8°C and used within 28 days. The fatty acid modification provides additional stability against enzymatic degradation in solution but does not eliminate the need for proper cold storage. Repeated freeze-thaw cycles degrade peptide integrity and should be avoided.

Every vial should be visually inspected before use. The reconstituted solution should be clear and free of particulates. Cloudiness, discoloration, or visible sediment indicates degradation, and the vial should not be used in research.

For full handling protocols across the broader peptide catalog, see our storage and reconstitution guide.

Sourcing Verified Retatrutide for Research

Retatrutide is one of the most counterfeited research peptides currently in circulation, driven by significant attention following the 2023 phase 2 obesity results. Independent testing data from grey-market suppliers regularly reveals products labeled “Retatrutide” that contain incorrect peptide sequences, related GLP-1 compounds (sometimes Tirzepatide or Semaglutide), substantially below-labeled peptide content, or in some cases no Retatrutide at all.

A credible Certificate of Analysis for Retatrutide should show three things at minimum: HPLC purity expressed as a percentage, mass spectrometry confirmation matching Retatrutide’s molecular weight of approximately 4731 g/mol, and an explicit distinction between peptide content and peptide mass. The mass spectrometry confirmation is particularly important — a peak at 4731 Da confirms Retatrutide, while peaks corresponding to Tirzepatide (approximately 4813 Da) or Semaglutide (approximately 4113 Da) indicate the vial contains a different GLP-1-class compound.

Kinetic Compounds publishes the full Certificate of Analysis for every batch of Retatrutide, with all testing performed by Janoshik Analytical, an independent third-party laboratory. Researchers can review the current batch report on the Retatrutide product page, and our broader testing methodology is documented on our lab testing and COA page.

For researchers comparing across the GLP-1 receptor agonist class, the Semaglutide and Tirzepatide glossary entries cover the single- and dual-agonist mechanisms that contextualize Retatrutide’s triple-agonist design. The full GLP-1 and metabolic research peptide catalog lists all related compounds with current Certificates of Analysis.

Comparing the GLP-1 receptor agonist class for research? Our complete GLP-1 and metabolic research peptide catalog covers Semaglutide, Tirzepatide, Retatrutide, and related compounds — all independently lab-tested with current Certificates of Analysis available.